ES2589079T3 - Tecnología de amplificación de ácido nucleíco acelerado isotérmicamente - Google Patents
Tecnología de amplificación de ácido nucleíco acelerado isotérmicamente Download PDFInfo
- Publication number
- ES2589079T3 ES2589079T3 ES10725825.3T ES10725825T ES2589079T3 ES 2589079 T3 ES2589079 T3 ES 2589079T3 ES 10725825 T ES10725825 T ES 10725825T ES 2589079 T3 ES2589079 T3 ES 2589079T3
- Authority
- ES
- Spain
- Prior art keywords
- primer
- primers
- region
- segment
- mother
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000003321 amplification Effects 0.000 title claims description 175
- 238000003199 nucleic acid amplification method Methods 0.000 title claims description 175
- 150000007523 nucleic acids Chemical class 0.000 title claims description 33
- 102000039446 nucleic acids Human genes 0.000 title claims description 31
- 108020004707 nucleic acids Proteins 0.000 title claims description 31
- 238000005516 engineering process Methods 0.000 title description 12
- 238000000034 method Methods 0.000 claims abstract description 175
- 108091093088 Amplicon Proteins 0.000 claims abstract description 166
- 239000002773 nucleotide Substances 0.000 claims abstract description 77
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 75
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 70
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 70
- 230000000295 complement effect Effects 0.000 claims abstract description 57
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 26
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 15
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 10
- 230000002194 synthesizing effect Effects 0.000 claims abstract description 3
- 238000007397 LAMP assay Methods 0.000 claims description 63
- 230000002441 reversible effect Effects 0.000 claims description 58
- 230000008569 process Effects 0.000 claims description 40
- 239000000523 sample Substances 0.000 claims description 34
- 238000001514 detection method Methods 0.000 claims description 21
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 230000037452 priming Effects 0.000 claims description 13
- 208000011738 Lichen planopilaris Diseases 0.000 claims description 11
- 102100026358 Lipoma-preferred partner Human genes 0.000 claims description 11
- 238000005755 formation reaction Methods 0.000 claims description 11
- 208000011797 pustulosis palmaris et plantaris Diseases 0.000 claims description 11
- 230000002068 genetic effect Effects 0.000 claims description 10
- 238000005259 measurement Methods 0.000 claims description 9
- 244000005700 microbiome Species 0.000 claims description 8
- 238000003556 assay Methods 0.000 claims description 6
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims description 6
- 235000011180 diphosphates Nutrition 0.000 claims description 6
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 claims description 5
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 claims description 5
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 claims description 5
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 claims description 5
- 239000007850 fluorescent dye Substances 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 108060001084 Luciferase Proteins 0.000 claims description 4
- 241000191967 Staphylococcus aureus Species 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 235000003869 genetically modified organism Nutrition 0.000 claims description 4
- 229960003085 meticillin Drugs 0.000 claims description 4
- 102000054765 polymorphisms of proteins Human genes 0.000 claims description 4
- 239000000758 substrate Substances 0.000 claims description 4
- 101000743006 Lactococcus lactis subsp. cremoris UPF0177 protein in abiGi 5'region Proteins 0.000 claims description 3
- 239000005089 Luciferase Substances 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 3
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims description 3
- 238000011002 quantification Methods 0.000 claims description 3
- 206010067484 Adverse reaction Diseases 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims description 2
- 241000233866 Fungi Species 0.000 claims description 2
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims description 2
- 229930010555 Inosine Natural products 0.000 claims description 2
- 241001430197 Mollicutes Species 0.000 claims description 2
- PJKKQFAEFWCNAQ-UHFFFAOYSA-N N(4)-methylcytosine Chemical compound CNC=1C=CNC(=O)N=1 PJKKQFAEFWCNAQ-UHFFFAOYSA-N 0.000 claims description 2
- 108091028664 Ribonucleotide Proteins 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 230000006838 adverse reaction Effects 0.000 claims description 2
- 229960002685 biotin Drugs 0.000 claims description 2
- 235000020958 biotin Nutrition 0.000 claims description 2
- 239000011616 biotin Substances 0.000 claims description 2
- 238000001962 electrophoresis Methods 0.000 claims description 2
- -1 for example Substances 0.000 claims description 2
- 229960003786 inosine Drugs 0.000 claims description 2
- 238000004949 mass spectrometry Methods 0.000 claims description 2
- 239000002336 ribonucleotide Substances 0.000 claims description 2
- 125000002652 ribonucleotide group Chemical group 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 206010041925 Staphylococcal infections Diseases 0.000 claims 2
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 claims 2
- 238000001668 nucleic acid synthesis Methods 0.000 claims 2
- 101000794020 Homo sapiens Bromodomain-containing protein 8 Proteins 0.000 claims 1
- 101001006782 Homo sapiens Kinesin-associated protein 3 Proteins 0.000 claims 1
- 101000615355 Homo sapiens Small acidic protein Proteins 0.000 claims 1
- WGKGADVPRVLHHZ-ZHRMCQFGSA-N N-[(1R,2R,3S)-2-hydroxy-3-phenoxazin-10-ylcyclohexyl]-4-(trifluoromethoxy)benzenesulfonamide Chemical compound O[C@H]1[C@@H](CCC[C@@H]1N1C2=CC=CC=C2OC2=C1C=CC=C2)NS(=O)(=O)C1=CC=C(OC(F)(F)F)C=C1 WGKGADVPRVLHHZ-ZHRMCQFGSA-N 0.000 claims 1
- 102100021255 Small acidic protein Human genes 0.000 claims 1
- 230000029918 bioluminescence Effects 0.000 claims 1
- 238000005415 bioluminescence Methods 0.000 claims 1
- 238000002848 electrochemical method Methods 0.000 claims 1
- 235000013311 vegetables Nutrition 0.000 claims 1
- 108020004414 DNA Proteins 0.000 description 55
- 108091028732 Concatemer Proteins 0.000 description 31
- 238000006073 displacement reaction Methods 0.000 description 24
- 238000006243 chemical reaction Methods 0.000 description 23
- 230000007246 mechanism Effects 0.000 description 23
- 239000002157 polynucleotide Substances 0.000 description 20
- 230000000694 effects Effects 0.000 description 18
- 238000012360 testing method Methods 0.000 description 16
- 241000186779 Listeria monocytogenes Species 0.000 description 13
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 12
- 239000013612 plasmid Substances 0.000 description 12
- 241000282326 Felis catus Species 0.000 description 11
- 230000009471 action Effects 0.000 description 10
- 239000012634 fragment Substances 0.000 description 9
- 101000773513 Methanopyrus kandleri (strain AV19 / DSM 6324 / JCM 9639 / NBRC 100938) Uncharacterized protein MK0525 Proteins 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 7
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 7
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 6
- 230000003466 anti-cipated effect Effects 0.000 description 6
- 238000011901 isothermal amplification Methods 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 241000186781 Listeria Species 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 238000003384 imaging method Methods 0.000 description 5
- 230000001133 acceleration Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- IRLPACMLTUPBCL-KQYNXXCUSA-N 5'-adenylyl sulfate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OS(O)(=O)=O)[C@@H](O)[C@H]1O IRLPACMLTUPBCL-KQYNXXCUSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 108090000331 Firefly luciferases Proteins 0.000 description 3
- 108060004795 Methyltransferase Proteins 0.000 description 3
- 108010091086 Recombinases Proteins 0.000 description 3
- 102000018120 Recombinases Human genes 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000013610 patient sample Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- SNBCLPGEMZEWLU-QXFUBDJGSA-N 2-chloro-n-[[(2r,3s,5r)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl]acetamide Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CNC(=O)CCl)[C@@H](O)C1 SNBCLPGEMZEWLU-QXFUBDJGSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 230000006819 RNA synthesis Effects 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 102000004523 Sulfate Adenylyltransferase Human genes 0.000 description 2
- 108010022348 Sulfate adenylyltransferase Proteins 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 101150008979 mecA gene Proteins 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 125000003835 nucleoside group Chemical group 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- 108010052418 (N-(2-((4-((2-((4-(9-acridinylamino)phenyl)amino)-2-oxoethyl)amino)-4-oxobutyl)amino)-1-(1H-imidazol-4-ylmethyl)-1-oxoethyl)-6-(((-2-aminoethyl)amino)methyl)-2-pyridinecarboxamidato) iron(1+) Proteins 0.000 description 1
- 108700031821 Bacteria invA Proteins 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 101100107522 Mus musculus Slc1a5 gene Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 101100489871 Rattus norvegicus Got2 gene Proteins 0.000 description 1
- 108700005711 Staphylococcus aureus SarH1 Proteins 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000011013 aquamarine Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 238000013178 mathematical model Methods 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000013615 primer Substances 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0910302.9A GB0910302D0 (en) | 2009-06-15 | 2009-06-15 | Nucleic acid amplification |
| GB0910302 | 2009-06-15 | ||
| PCT/GB2010/001169 WO2010146349A1 (en) | 2009-06-15 | 2010-06-15 | Stem accelerated isothermal nucleic acid amplification technology |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2589079T3 true ES2589079T3 (es) | 2016-11-10 |
Family
ID=40940851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10725825.3T Active ES2589079T3 (es) | 2009-06-15 | 2010-06-15 | Tecnología de amplificación de ácido nucleíco acelerado isotérmicamente |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9410190B2 (enExample) |
| EP (1) | EP2443253B1 (enExample) |
| JP (2) | JP5907864B2 (enExample) |
| CN (1) | CN102652176B (enExample) |
| AU (1) | AU2010261541B2 (enExample) |
| CA (1) | CA2765406C (enExample) |
| ES (1) | ES2589079T3 (enExample) |
| GB (1) | GB0910302D0 (enExample) |
| WO (1) | WO2010146349A1 (enExample) |
| ZA (1) | ZA201109493B (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102369298B (zh) | 2009-01-30 | 2017-03-22 | 牛津纳米孔技术有限公司 | 跨膜测序中用于核酸构建体的衔接体 |
| DK2633071T3 (en) | 2010-10-27 | 2017-01-30 | Harvard College | COMPOSITIONS OF "MAINTENANCE" PRIMER DUPLEXES AND METHODS OF USE |
| CA2835283C (en) | 2011-05-24 | 2019-08-06 | Elitech Holding B.V. | Detection of methicillin-resistant staphylococcus aureus |
| CN103827320B (zh) | 2011-07-25 | 2017-04-26 | 牛津纳米孔技术有限公司 | 使用跨膜孔进行双链多核苷酸测序的发夹环方法 |
| WO2014013259A1 (en) | 2012-07-19 | 2014-01-23 | Oxford Nanopore Technologies Limited | Ssb method |
| CN105209634B (zh) | 2013-03-08 | 2020-05-12 | 牛津纳米孔技术公司 | 酶停滞方法 |
| GB201314695D0 (en) | 2013-08-16 | 2013-10-02 | Oxford Nanopore Tech Ltd | Method |
| WO2014145291A1 (en) | 2013-03-15 | 2014-09-18 | Theranos, Inc. | Nucleic acid amplification |
| US9677981B2 (en) | 2013-03-15 | 2017-06-13 | 3M Innovative Properties Company | Sample concentrator and method of use |
| US10450595B2 (en) | 2013-03-15 | 2019-10-22 | Theranos Ip Company, Llc | Nucleic acid amplification |
| BR112015023398A8 (pt) | 2013-03-15 | 2022-08-23 | Theranos Inc | Métodos para amplificar ácidos nucléicos |
| CN105452480B (zh) * | 2013-08-09 | 2020-01-31 | 基因生物系统股份有限公司 | 经由剪刀状结构的dna扩增(dasl) |
| CN111378568A (zh) | 2013-09-06 | 2020-07-07 | 赛拉诺斯知识产权有限责任公司 | 用于检测感染性疾病的系统和方法 |
| CN103497947B (zh) * | 2013-09-13 | 2015-08-12 | 浙江国际旅行卫生保健中心 | 一种体外新型快速环介导等温扩增方法、体外检测甲型h1n1流感病毒的试剂及方法 |
| CA2927315A1 (en) * | 2013-11-22 | 2015-05-28 | Theranos, Inc. | Nucleic acid amplification |
| US11859246B2 (en) | 2013-12-11 | 2024-01-02 | Accuragen Holdings Limited | Methods and compositions for enrichment of amplification products |
| EP3495506B1 (en) | 2013-12-11 | 2023-07-12 | AccuraGen Holdings Limited | Methods for detecting rare sequence variants |
| US11286519B2 (en) | 2013-12-11 | 2022-03-29 | Accuragen Holdings Limited | Methods and compositions for enrichment of amplification products |
| GB201403096D0 (en) | 2014-02-21 | 2014-04-09 | Oxford Nanopore Tech Ltd | Sample preparation method |
| US10716587B2 (en) | 2014-06-13 | 2020-07-21 | Surgis Medical Llc | Surgical device with light |
| CN106661600B (zh) * | 2014-07-16 | 2021-04-06 | 唐恩生物科技股份有限公司 | 用于扩增核酸样品的等温方法 |
| WO2016073353A1 (en) | 2014-11-03 | 2016-05-12 | Tangen Biosciences, Inc. | Apparatus and method for cell, spore, or virus capture and disruption |
| EP3250716B1 (en) | 2015-01-30 | 2021-07-07 | President and Fellows of Harvard College | Microscope-free imaging |
| US10612073B2 (en) | 2015-02-26 | 2020-04-07 | Hitachi High-Technologies Corporation | Method for constructing nucleic acid molecule |
| US10260090B2 (en) | 2015-07-16 | 2019-04-16 | Arizona Board Of Regents On Behalf Of Arizona State University | Accelerated isothermal amplification of DNA |
| HK1259101A1 (zh) | 2015-10-09 | 2019-11-22 | Accuragen Holdings Limited | 用於富集扩增产物的方法及组合物 |
| WO2017096322A1 (en) | 2015-12-03 | 2017-06-08 | Accuragen Holdings Limited | Methods and compositions for forming ligation products |
| EP4239079B1 (en) | 2016-02-17 | 2025-12-17 | President And Fellows Of Harvard College | Molecular programming tools |
| EP3458586B1 (en) | 2016-05-16 | 2022-12-28 | Accuragen Holdings Limited | Method of improved sequencing by strand identification |
| GB201609220D0 (en) | 2016-05-25 | 2016-07-06 | Oxford Nanopore Tech Ltd | Method |
| CN107488656B (zh) | 2016-06-13 | 2020-07-17 | 陆欣华 | 一种核酸等温自扩增方法 |
| JP6966052B2 (ja) | 2016-08-15 | 2021-11-10 | アキュラーゲン ホールディングス リミテッド | 稀な配列変異体を検出するための組成物および方法 |
| US11492661B2 (en) | 2017-01-10 | 2022-11-08 | President And Fellows Of Harvard College | Multiplexed signal amplification |
| US11035010B2 (en) | 2017-12-14 | 2021-06-15 | Medicinal Genomics Corporation | Methods and kits for classifying cannabinoid production in cannabis plants |
| EP3743525A4 (en) | 2018-01-26 | 2021-09-29 | President and Fellows of Harvard College | PROXIMITY DETECTION METHODS AND COMPOSITIONS |
| GB201807793D0 (en) | 2018-05-14 | 2018-06-27 | Oxford Nanopore Tech Ltd | Method |
| WO2019241290A1 (en) | 2018-06-12 | 2019-12-19 | Accuragen Holdings Limited | Methods and compositions for forming ligation products |
| CN114045330B (zh) * | 2021-12-23 | 2024-02-09 | 川北医学院附属医院 | 一种基于滑动复制的核酸等温扩增方法 |
| CN118621045A (zh) * | 2024-08-14 | 2024-09-10 | 天健生物制药（天津）有限公司 | 基于lamp的鸟分枝杆菌检测的组合物和试剂盒 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5866336A (en) * | 1996-07-16 | 1999-02-02 | Oncor, Inc. | Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon |
| ES2327712T3 (es) * | 2000-09-19 | 2009-11-03 | Eiken Kagaku Kabushiki Kaisha | Procedimiento para sintetizar polinucleotidos. |
| WO2002090538A1 (en) * | 2001-05-08 | 2002-11-14 | Eiken Kagaku Kabushiki Kaisha | Method of synthesizing nucleic acid |
| GB0218215D0 (en) | 2002-08-06 | 2002-09-11 | Tepnel Medical Ltd | Amplification of nucleic acids |
| WO2007025281A2 (en) | 2005-08-24 | 2007-03-01 | Applera Corporation | A method to quantify sirnas, mirnas and polymorphic mirnas |
| JP4580875B2 (ja) * | 2006-01-20 | 2010-11-17 | 株式会社東芝 | 核酸検出法のためのプライマーの設計方法 |
| JP2008029333A (ja) | 2006-07-03 | 2008-02-14 | Fujifilm Corp | 新規遺伝子増幅法に用いられるプライマー |
| WO2008043987A2 (en) | 2006-10-09 | 2008-04-17 | Oxitec Limited | Methods for amplifying and detecting nucleic acid sequences |
| JP4490988B2 (ja) * | 2007-04-26 | 2010-06-30 | 株式会社東芝 | 血清アミロイドａ１（ｓａａ１）の遺伝子型を検出するための核酸プライマーセット、キット、及び該プライマーセットを用いた検出方法 |
| US8748100B2 (en) | 2007-08-30 | 2014-06-10 | The Chinese University Of Hong Kong | Methods and kits for selectively amplifying, detecting or quantifying target DNA with specific end sequences |
-
2009
- 2009-06-15 GB GBGB0910302.9A patent/GB0910302D0/en not_active Ceased
-
2010
- 2010-06-15 CA CA2765406A patent/CA2765406C/en active Active
- 2010-06-15 CN CN201080035868.5A patent/CN102652176B/zh active Active
- 2010-06-15 JP JP2012515553A patent/JP5907864B2/ja not_active Expired - Fee Related
- 2010-06-15 US US13/377,704 patent/US9410190B2/en active Active
- 2010-06-15 ES ES10725825.3T patent/ES2589079T3/es active Active
- 2010-06-15 WO PCT/GB2010/001169 patent/WO2010146349A1/en not_active Ceased
- 2010-06-15 AU AU2010261541A patent/AU2010261541B2/en not_active Ceased
- 2010-06-15 EP EP10725825.3A patent/EP2443253B1/en active Active
-
2011
- 2011-12-22 ZA ZA2011/09493A patent/ZA201109493B/en unknown
-
2015
- 2015-10-09 JP JP2015201347A patent/JP6106732B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20120157326A1 (en) | 2012-06-21 |
| JP2012529904A (ja) | 2012-11-29 |
| US9410190B2 (en) | 2016-08-09 |
| CN102652176A (zh) | 2012-08-29 |
| WO2010146349A1 (en) | 2010-12-23 |
| CN102652176B (zh) | 2016-09-28 |
| GB0910302D0 (en) | 2009-07-29 |
| AU2010261541B2 (en) | 2016-03-10 |
| EP2443253A1 (en) | 2012-04-25 |
| AU2010261541A1 (en) | 2012-02-02 |
| CA2765406A1 (en) | 2010-12-23 |
| JP6106732B2 (ja) | 2017-04-05 |
| CA2765406C (en) | 2019-02-26 |
| JP2016041070A (ja) | 2016-03-31 |
| JP5907864B2 (ja) | 2016-04-26 |
| EP2443253B1 (en) | 2016-06-08 |
| ZA201109493B (en) | 2015-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2589079T3 (es) | Tecnología de amplificación de ácido nucleíco acelerado isotérmicamente | |
| ES2618127T3 (es) | Composiciones de dúplex de cebador de extremos cohesivos y métodos de uso | |
| US12390812B2 (en) | Apparatus and methods for molecular diagnostics | |
| ES2927463T3 (es) | Diagnósticos basados en el sistema efector CRISPR | |
| ES2880335T3 (es) | Métodos y composiciones para la preparación rápida de bibliotecas de ácidos nucleicos | |
| Yang et al. | Comparison of next-generation droplet digital PCR (ddPCR) with quantitative PCR (qPCR) for enumeration of Cryptosporidium oocysts in faecal samples | |
| Nolan et al. | PCR technology: current innovations | |
| Sun et al. | ATP-induced helicase slippage reveals highly coordinated subunits | |
| ES2754251T3 (es) | Secuencia cubierta de conversión de ADN y métodos de detección | |
| JP2013501508A5 (enExample) | ||
| ES3020682T3 (en) | Amplification of single stranded cdna | |
| KR20160093687A (ko) | 미세 조정된 초특정 핵산 하이브리다이제이션 프로브 | |
| ES2685710T3 (es) | Kits que comprenden controles para amplificación de ácido nucleico | |
| ES2791280T3 (es) | Método de detección, composición y kit basados en reacciones en cascada de ADN amplificador de señal con extensión de la diana | |
| ES2729637T3 (es) | Amplificación de ácidos nucleicos | |
| CN102459626A (zh) | 核酸扩增方法 | |
| ES2879823T3 (es) | Amplificación de ácidos nucleicos | |
| WO2013154138A1 (ja) | 分子ビーコン型プローブを用いた標的核酸の検出方法 | |
| ES2697401T3 (es) | Cebadores modificados para amplificación y detección de ácidos nucleicos | |
| Meng et al. | Lineal DNA logic gate for microRNA diagnostics with strand displacement and fluorescence resonance energy transfer | |
| Kim et al. | Enhancing multiplex detection capabilities of the Cas12a/blocker DNA system | |
| JP2017538418A (ja) | 抗生物質耐性細菌を検出する方法および組成物 | |
| Ming et al. | Eliminating the secondary structure of targeting strands for enhancement of DNA probe based low-abundance point mutation detection | |
| Roberts et al. | Molecular cardiology and genetics in the 21st century—a primer | |
| ES2449665B2 (es) | Procedimiento para el diagnóstico clínico de una enfermedad infecciosa basada en el empleo de la PCR cuantitativa, oligonucleótidos marcados de 8 a 9 nucleótidos de longitud y la UNG del Bacalao del Atlántico (Gadus morhua). |